• 11/26/2024

Eli Lilly’s anti-obesity drug Zepbound significantly reduced the risk of Type 2 diabetes among people with excess weight and elevated blood-sugar levels in a new study.

Wall Street Journal

Eli Lilly’s anti-obesity drug Zepbound significantly reduced the risk of Type 2 diabetes among people with excess weight and elevated blood-sugar levels in a new study.

https://www.wsj.com/health/pharma/eli-lilly-says-weight-loss-drug-sharply-reduces-diabetes-progression-96a1100b